HUTCHMED China Ltd (HCM) - Total Assets
Based on the latest financial reports, HUTCHMED China Ltd (HCM) holds total assets worth GBX1.78 Billion GBX as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
HUTCHMED China Ltd - Total Assets Trend (2005–2024)
This chart illustrates how HUTCHMED China Ltd's total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
HUTCHMED China Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
HUTCHMED China Ltd's total assets of GBX1.78 Billion consist of 83.7% current assets and 16.3% non-current assets.
| Asset Category | Amount (GBX) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | GBX0.00 | 12.1% |
| Accounts Receivable | GBX167.74 Million | 13.2% |
| Inventory | GBX50.40 Million | 4.0% |
| Property, Plant & Equipment | GBX0.00 | 0.0% |
| Intangible Assets | GBX167.74 Million | 13.2% |
| Goodwill | GBX0.00 | 0.0% |
Asset Composition Trend (2005–2024)
This chart illustrates how HUTCHMED China Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: HUTCHMED China Ltd's current assets represent 83.7% of total assets in 2024, an increase from 47.7% in 2005.
- Cash Position: Cash and equivalents constituted 12.1% of total assets in 2024, up from 8.9% in 2005.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 13.0% of total assets, a decrease from 19.0% in 2005.
- Asset Diversification: The largest asset category is intangible assets at 13.2% of total assets.
HUTCHMED China Ltd Competitors by Total Assets
Key competitors of HUTCHMED China Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩642.17 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp Preferred
KO:000105
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
|
Yuyu Pharma
KO:000220
|
Korea | ₩202.42 Billion |
|
Ildong Holdings Co Ltd
KO:000230
|
Korea | ₩813.62 Billion |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423
|
China | CN¥12.75 Billion |
HUTCHMED China Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.65 | 2.81 | 3.35 |
| Quick Ratio | 4.65 | 2.68 | 3.23 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | GBX1.25 Billion | GBX674.97 Million | GBX372.34 Million |
HUTCHMED China Ltd - Advanced Valuation Insights
This section examines the relationship between HUTCHMED China Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.97 |
| Latest Market Cap to Assets Ratio | 0.02 |
| Asset Growth Rate (YoY) | -0.4% |
| Total Assets | GBX1.27 Billion |
| Market Capitalization | $23.00 Million USD |
Valuation Analysis
Below Book Valuation: The market values HUTCHMED China Ltd's assets below their book value (0.02x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: HUTCHMED China Ltd's assets decreased by 0.4% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for HUTCHMED China Ltd (2005–2024)
The table below shows the annual total assets of HUTCHMED China Ltd from 2005 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | GBX1.27 Billion | -0.44% |
| 2023-12-31 | GBX1.28 Billion | +24.32% |
| 2022-12-31 | GBX1.03 Billion | -25.00% |
| 2021-12-31 | GBX1.37 Billion | +89.56% |
| 2020-12-31 | GBX724.12 Million | +55.68% |
| 2019-12-31 | GBX465.12 Million | -12.59% |
| 2018-12-31 | GBX532.12 Million | -11.01% |
| 2017-12-31 | GBX597.93 Million | +74.61% |
| 2016-12-31 | GBX342.44 Million | +49.05% |
| 2015-12-31 | GBX229.75 Million | +4.94% |
| 2014-12-31 | GBX218.94 Million | +17.92% |
| 2013-12-31 | GBX185.67 Million | -11.36% |
| 2012-12-31 | GBX209.47 Million | +7.54% |
| 2011-12-31 | GBX194.77 Million | +21.79% |
| 2010-12-31 | GBX159.93 Million | +25.18% |
| 2009-12-31 | GBX127.75 Million | +8.31% |
| 2008-12-31 | GBX117.96 Million | -7.53% |
| 2007-12-31 | GBX127.56 Million | -4.12% |
| 2006-12-31 | GBX133.04 Million | +111.58% |
| 2005-12-31 | GBX62.88 Million | -- |
About HUTCHMED China Ltd
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. The company offers Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), b… Read more